Current report no. 11/2022 – Positive outcome of FDA’s assessment process of the IND application concerning the commencement of a clinical trial for Falkieri (Celon’s esketamine DPI)
24 May 2022 | News
In connection with current report No. 9/2022 of 20 April 2022 on Celon Pharma S.A. (the “Company”) submitting an application to the Food and Drug Administration (FDA), the Management Board of the Company informs that today it has received information from the American regulatory authority that the Company may commence clinical trials of Falkieri (Celon’sRead more »
Welcome to Celon Pharma S.A.
Celon Pharma S.A. is an integrated pharmaceutical company which conducts advanced research and manufactures modern drugs. The company is also a successful marketing authorisation holder for it products. The drugs we offer help thousands of patients lead a better and longer life.
News
- Current report no. 11/2022 – Positive outcome of FDA’s assessment process of the IND application concerning the commencement of a clinical trial for Falkieri (Celon’s esketamine DPI)In connection with current report No. 9/2022 of 20 April 2022 on Celon Pharma S.A. (the “Company”) submitting an application to the Food and Drug Administration (FDA), the Management BoardRead more »
- Celon Pharma at the #BIO2022 ConventionOn 13-16 June this year, representatives of Celon Pharma will take part in this year's BIO International Convention. This is the world's largest meeting of representatives of the life industry,Read more »
- Celon Pharma joined the beneficiaries of the international project ORBIS – Open Research Biopharmaceutical Internships SupportThe overall objective of the ORBIS project is to improve the development of innovative and generic medicines. The way to achieve this goal is the cooperation of representatives of academicRead more »
Research and development
We create innovative drugs, that will change the lives of patients globally
Products
We are leaders in
inhalation technology
